Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cisplatin Chemoradiation for TNBC
NCT00603408Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2007
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin in triple-negative breast cancer (TNBC), sponsored by Washington University School of Medicine. Primary endpoint: Overall Response Rate at Week 13. Started Dec 2007; status: terminated.
02
Drugs
cisplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00603408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00603408.